These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15534791)

  • 1. Regulatory advice on evaluation of the proarrhythmic potential of drugs.
    Stockbridge N; Throckmorton DC
    J Electrocardiol; 2004; 37 Suppl():40-1. PubMed ID: 15534791
    [No Abstract]   [Full Text] [Related]  

  • 2. A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies.
    Shryock JC; Song Y; Wu L; Fraser H; Belardinelli L
    J Electrocardiol; 2004; 37 Suppl():34-9. PubMed ID: 15534790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Concern of pharmacovigilance: proarrhythmic effects of medications in current use].
    Caron J; Gautier S; Couderc E; Bordet R
    Arch Pediatr; 1999; 6 Suppl 2():231s-232s. PubMed ID: 10370490
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.
    Hooimeyer A; Bhasale A; Perry L; Fabbri A; Mohammad A; McEwin E; Mintzes B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00680. PubMed ID: 33169534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Health Canada protect Canadians from unsafe drugs?
    Hébert PC; Stanbrook MB; MacDonald N; Flegel K; Coutts J; MacLeod S
    CMAJ; 2011 Jul; 183(10):1125-6. PubMed ID: 21502342
    [No Abstract]   [Full Text] [Related]  

  • 7. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential Role of the J-T
    Vicente J; Strauss DG; Upreti VV; Fossler MJ; Sager PT; Noveck R
    J Clin Pharmacol; 2019 Jul; 59(7):909-914. PubMed ID: 30907981
    [No Abstract]   [Full Text] [Related]  

  • 11. [Arrhythmogenic action of drugs].
    Metelitsa VI
    Eksp Klin Farmakol; 2005; 68(2):68-77. PubMed ID: 15934372
    [No Abstract]   [Full Text] [Related]  

  • 12. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety Pharmacology World Europe 2008--Healthcare Communications' Second Annual Conference.
    Lakeram M
    IDrugs; 2009 Jan; 12(1):26-8. PubMed ID: 19127501
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open Letter to Health Canada.
    Papp K; Albrecht L; Barber K; Bourcier M; Dion PL; Freiman A; Gooderham M; Guenther L; Gulliver W; Hong CH; Lynde C; Poulin Y; Siddha S; Toole J; Toth D; Vender R; Wasel N; Wiseman M
    J Cutan Med Surg; 2017; 21(3):195-196. PubMed ID: 28903599
    [No Abstract]   [Full Text] [Related]  

  • 16. Reporting drug side effects: signals and noise.
    Avorn J
    JAMA; 1990 Apr; 263(13):1823. PubMed ID: 2313853
    [No Abstract]   [Full Text] [Related]  

  • 17. Basic Cardiac Electrophysiology and Common Drug-induced Arrhythmias.
    Lee A; Pickham D
    Crit Care Nurs Clin North Am; 2016 Sep; 28(3):357-71. PubMed ID: 27484663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How the FDA handles GI drug safety.
    Lewis JH
    Am J Gastroenterol; 2012 Aug; 107(8):1264; author reply 1264-5. PubMed ID: 22859005
    [No Abstract]   [Full Text] [Related]  

  • 19. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.